A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers at Stanford have developed a new, patented strategy to enhance anti-tumor immune responses to treat cancer. Cancer is the second leading cause of death in the United States and inflicts a tremendous burden on public health.
Researchers in Dr. James Chen's lab at Stanford have discovered novel Hedgehog (Hh) pathway inhibitors that may serve as anti-cancer therapeutics. The Hh pathway plays a critical role in patterning, homeostasis, and oncogenic transformation of multiple tissues.
Stanford researchers have proposed antibody-based reduction of Neuromedin (NMU) signaling as a therapeutic strategy to improve glucose metabolism in multiple physiological or disease states, including obesity, diabetes, and cancer where NMU levels are elevated.
The standard treatment for hepatitis C virus (HCV) is poorly tolerated and ineffective in a large subset of HCV patients. Scientists at Stanford and UCSF have developed new therapeutic leads for HCV that also have potential to be broad-spectrum anti-infectives.
Hydrogel-based tissue engineering scaffolds are widely used for culturing cells in three dimensions (3D) due to their tissue-like water content, tunable biochemical and physical properties, and ease of cell encapsulation and distribution in 3D.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.